Thermo Fisher Scientific uPAR Monoclonal Antibody (R-4)

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

View 3 publications 3 publications

Immunohistochemistry (Paraffin) (IHC (P))

Assay-dependent

-

Immunohistochemistry (Frozen) (IHC (F))

Assay-dependent

-

Flow Cytometry (Flow)

Assay-dependent

-

ELISA (ELISA)

Assay-dependent

-

Product Specifications

Published species

Human

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

R-4

Immunogen

Native human uPAR.

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1.09 mg/mL

Storage conditions

4° C, store in dark

Shipping conditions

Wet ice

RRID

AB_2539793

Product Specific Information

Specificity: MON R-4-02 does not cross-react with mouse uPAR, human uPA, human tPA or human PAI-1 when tested by ELISA and immunoblotting.

Reactivity: MON R-4-02 reacts with domain 3 in immunoprecipitation using proteolytic fragments of recombinant suPAR. This antibody is suitable for Western blotting of non-reduced proteins and can be used as a detection antibody in ELISA applications.

NOTE: Concentration is lot-dependent and can vary from 0.85-1.15 mg/mL

Target Information

The urokinase-type plasminogen activator receptor is a key molecule in the regulation of cell-surface plasminogen activation and plays an important role in many normal as well as pathologic processes. The human PLAUR cDNA encodes 335 amino acids including a predicted signal peptide of 22 residues and a hydrophobic C-terminal portion. It produces a highly glycosylated protein of about 50 kD in monocytes where it is anchored to the plasma membrane by glycosyl-phosphatidylinositol linkage. PLAUR, also known as UPAR, is directly associated with the carbohydrate-binding domain of SELL in the membrane of neutrophils, an association analogous to that between PLAUR and beta-2 integrins. PLAUR-mediated calcium mobilization is SELL dependent. UPAR mRNA levels correlate with the invasive potential of endometrial carcinomas and show a 33-fold increase in UPAR mRNA levels in advanced clinical stage endometrial tumors compared with normal endometrial tissue. Furthermore, the increase in UPAR mRNA levels correlated linearly with the progression of disease stage. UPAR protein expressioin correlated positively with rate of recurrence and mortality in patients with endometrial cancer. UPAR appears to be a useful prognostic marker for advanced endometrial cancer.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.